Revolution Medicines (RVMD) Share-based Compensation (2019 - 2026)

Revolution Medicines' Share-based Compensation history runs 8 years deep, the most recent figure standing at $87.3 million for Q1 2026.

• In Q1 2026, Share-based Compensation rose 248.03% year-over-year to $87.3 million; the TTM figure through Mar 2026 stood at $180.6 million (up 105.06% YoY), while the FY2025 annual figure was $118.4 million, up 49.49% from the prior year.
• Share-based Compensation was $87.3 million for Q1 2026 at Revolution Medicines, up from $33.7 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $87.3 million in Q1 2026 to a low of $6.6 million in Q1 2022.
• Historically, Share-based Compensation has averaged $22.2 million across 5 years, with a median of $19.8 million in 2024.
• The sharpest annual moves came in 2024 and 2026: Share-based Compensation retreated 11.75% in 2024, then jumped 248.03% in 2026.
• A 5-year view of Share-based Compensation shows it stood at $8.3 million in 2022, then surged by 205.76% to $25.4 million in 2023, then slipped by 11.75% to $22.4 million in 2024, then soared by 50.17% to $33.7 million in 2025, then surged by 159.08% to $87.3 million in 2026.
• The last three Share-based Compensation figures came in at $87.3 million (Q1 2026), $33.7 million (Q4 2025), and $30.8 million (Q3 2025), per Business Quant data.